# A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

> **NCT00904748** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 47 (actual)

## Conditions studied

- Erectile Dysfunction

## Interventions

- **DRUG:** sildenafil citrate 100 mg CT
- **DRUG:** sildenafil citrate 100 mg CT
- **DRUG:** Viagra®

## Key facts

- **NCT ID:** NCT00904748
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904748, "A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00904748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*